About: Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 30 June 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована в червні 2009 (uk) scientific article published on 30 June 2009 (en) مقالة علمية نشرت في 30 يونيو 2009 (ar)
publication date	wds:Q37287413-A6A5F056-554A-4210-9337-487492D4529C
publication date	2009-06-30 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37287413-CE84675F-F51A-49A8-91B3-481D1CDA9ED5
language of work or name	English
exact match	wds:Q37287413-4B1CD059-CDD4-475B-9987-B79F8A55EF69
exact match	https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605162
cites work	wds:Q37287413-2224CEC7-4493-463C-88A7-57DD26479A72 wds:Q37287413-32925C21-DADF-4B69-A429-B44F9E2657FE wds:Q37287413-32E95B68-9928-4A4B-9CC5-61B853CDECAE wds:Q37287413-3C462948-EF49-4ED8-AD93-57C4F3E7CCF6 wds:Q37287413-45A6298C-203D-45CB-9199-03F91BF1CA3A wds:Q37287413-5AEA8DCA-C484-491D-AF0D-1272112E84B0 wds:Q37287413-67B46C46-53AA-4C56-94B0-2758C2150814 wds:Q37287413-7B277288-F809-4F96-91ED-0099E603CE5D wds:Q37287413-8BABC0A2-A223-48B5-B214-68E33EF69942 wds:Q37287413-9062549D-E251-4279-BB16-9B905E48326F wds:Q37287413-B093E143-7BA1-4412-906D-E3A4A0BE169E wds:Q37287413-B50169C3-D25B-4B3F-827F-AD1F7186EE15 wds:Q37287413-D3C4045E-DFCB-4EBB-BC0F-1537E712155B wds:Q37287413-FB9F1AE2-E6CC-4297-A4A0-66E8BFD949DB
cites work	American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects An endotoxin-induced serum factor that causes necrosis of tumors Impaired angiogenesis in aminopeptidase N-null mice Targeted agents: the rules of combination Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancy Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration
author name string	wds:Q37287413-22B022C8-A446-433C-B95D-9917F6433988 wds:Q37287413-67F2C19C-518F-4010-9455-40CCB5748A04 wds:Q37287413-7B926427-C0EB-4533-8AD8-DB0C5CDA6199 wds:Q37287413-AC376A74-93C6-4007-9480-226F801B1475 wds:Q37287413-B88EB7AB-AA1B-4F3C-9976-849E3B875292 wds:Q37287413-BAAC9E33-2E60-4811-B8AB-D18830AF2B9D wds:Q37287413-D28093C0-87B6-41E7-9369-CE73F9E720F7 wds:Q37287413-F2198691-7D01-4BE3-92BE-5551760EE113 wds:Q37287413-F44F48A4-6DF2-4FCD-86CE-CCCE86A71CAE wds:Q37287413-F82AC12F-2A89-4CA1-927C-660934A8ED2D
author name string	C Bordignon A Santoro C J A Punt A Lambiase C M L van Herpen E Bennicelli F Caligaris Cappio G Citterio J N H Timmer-Bonte V Gregorc
rdfs:label	Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (en) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (nl) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (ast)
skos:prefLabel	Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (en) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (nl) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (ast)
name	Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (en) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (nl) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (ast)
author	wds:Q37287413-42C8A2F2-E26D-41A7-8360-CA8E687D487E
author	Armando Santoro
title	wds:Q37287413-BCCB8690-D0B3-4FB8-AF1F-4A05AF09867E
title	Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (en)
page(s)	wds:Q37287413-BA83C988-31D8-473F-9AE7-EF500BDA791A
page(s)	219-224
instance of	wds:Q37287413-9974B1B6-DE77-4DD1-9AB8-5598C073D661
instance of	scholarly article
main subject	wds:Q37287413-56F5E8D7-DE99-4264-99A5-7630A9220E57 wds:Q37287413-AB6B7632-534E-4734-A316-A429FDE7812F wds:Q37287413-C04E4ABB-8C11-4D4B-856B-5FF86022EF35
main subject	wd:Q18032037 wd:Q18936 Patients
PubMed ID	wds:Q37287413-F7C7649F-2166-4893-9144-D077B691F2D8
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19568235
PubMed ID	19568235
published in	wds:Q37287413-A04AAB58-FE2A-43E9-81F9-045C63417F18
published in	British Journal of Cancer
issue	wds:Q37287413-3AEE21C6-C893-4665-9FE3-DFB86E8015BE

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software